Foghorn Therapeutics Inc Dossier - Source-backed chat

Foghorn Therapeutics Inc

FHTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.21

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.92Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $173.4M

Enterprise Value $105.3M

Shares Outstanding 59.4M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Foghorn Therapeutics is a clinical-stage biotechnology company pioneering precision medicines targeting the chromatin regulatory system via its proprietary Gene Traffic Control platform. The investment thesis is anchored on the upcoming mid-2026 clinical catalyst for its lead asset, FHD-909 (a selective SMARCA2 inhibitor partnered with Eli Lilly), which is currently in Phase 1 dose escalation for SMARCA4-mutant solid tumors. Preclinical data presented at AACR 2026 demonstrated complete and durable tumor regression when combined with anti-PD-1 therapy, highlighting significant combination potential. Backed by a strong balance sheet with $183.6 million in cash (runway into 1H 2028) following a $50 million financing in January 2026, Foghorn is well-positioned to advance its pipeline of selective degraders (CBP, EP300, and ARID1B) toward IND-enabling milestones.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$11.44

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$9.0020%

FHD-909 Phase 1 data reveals dose-limiting toxicities or insufficient clinical efficacy, leading to a delay or termination of the Eli Lilly partnership. Preclinical safety advantages of the selective CBP and EP300 degraders fail to replicate in IND-enabling toxicology studies, resulting in program delays. The stock experiences significant downward pressure as the market discounts the platform's clinical viability, forcing the company to seek dilutive financing earlier than expected.

Base CaseCentral scenario

$11.4450%

Matches the consensus mean

FHD-909 Phase 1 data demonstrates solid, dose-dependent target engagement and manageable safety, justifying progression into dose-expansion cohorts under the Lilly collaboration. The selective CBP and EP300 degrader programs remain on track to complete IND-enabling studies in late 2026, with IND filings planned for 2027. The company maintains its cash runway into 1H 2028, keeping dilution risks low in the near term.

Bull CaseUpside scenario

$14.0030%

FHD-909 Phase 1 dose-escalation data in mid-2026 shows exceptional efficacy and a clean safety profile, triggering a rapid transition to Phase 1b dose-expansion cohorts funded by Eli Lilly. Preclinical synergy with anti-PD-1 and KRAS inhibitors translates successfully to human trials, establishing FHD-909 as a backbone therapy in SMARCA4-mutant NSCLC. Concurrently, the selective CBP and EP300 degraders successfully complete IND-enabling studies ahead of schedule, attracting further high-value pharmaceutical partnerships and driving substantial upward valuation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

High-value strategic collaboration with Eli Lilly for lead asset FHD-909, validating the platform and sharing clinical development costs.
Robust cash position of $183.6 million as of Q1 2026, providing a solid runway into the first half of 2028 and reducing near-term financing risk.
Proprietary Gene Traffic Control platform targeting genetically determined dependencies in the chromatin regulatory system, creating a highly differentiated oncology pipeline.
Promising preclinical data presented at AACR 2026 showing complete tumor regression and immune memory for FHD-909 in combination with immunotherapy.

Key Investment Risks

High clinical development risk associated with early-stage oncology assets; failure of FHD-909 in Phase 1 would severely impact the company's valuation.
Intense competition in the precision oncology space, particularly from other companies targeting the BAF complex and chromatin regulatory factors.
Dependence on strategic partners for the commercialization and late-stage development of key pipeline candidates.
Long-term capital requirements; despite the current runway, the company will eventually require substantial additional funding to advance its pipeline through late-stage trials.

Thesis Invalidation Triggers

A go/no-go decision by Eli Lilly to terminate or significantly scale back the FHD-909 development program following Phase 1 data.
Unanticipated severe adverse safety events or dose-limiting toxicities in the FHD-909 Phase 1 trial.
Failure to initiate IND-enabling studies for the selective CBP or EP300 degrader programs by the end of 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.